Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case–control study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The objective of this study was to evaluate the mortality of and risk factors for bacteriuria due to carbapenem-resistant Klebsiella pneumoniae (CRKp) versus carbapenem-susceptible K. pneumoniae (CSKp) producing extended spectrum β lactamase (ESBL).
This was a retrospective case–control study in which 135 case-patients with bacteriuria due to CRKp were compared with 127 control patients with CSKp producing ESBL. In a first step, multivariate Cox regression and Kaplan–Meier survival analysis models were used to determine the difference in mortality between the two groups and risk factors for mortality. In a second step, a univariate analysis was used to identify risk factors for CRKp colonization.
There were no significant demographic or clinical differences between the groups. In-hospital mortality in the study and control groups was 29 and 25 %, respectively (non-significant difference). Multivariate analysis revealed that the most important risk factor for mortality in both groups was being bed ridden [hazard ratio 2.2, 95 % confidence interval (CI) 1.23–3.93; P = 0.008]. Patients with CRKp bacteriuria had a longer hospitalization time with a mean ± standard deviation of 28 ± 33 days compared to 22 ± 28 days in the control group (P < 0.05). Several univariate risk factors for acquiring CRKp bacteriuria were identified: antibiotic use [odds ratio (OR) 1.93, 95 % CI 1.18–3.17, p = 0.008], especially colistin (OR 2.04, 95 % CI 1.04–4.02; P = 0.036), presence of a urinary catheter (OR 2.09, 95 % CI 1.2–3.63; P = 0.008), surgery (OR 3.94, 95 % CI 1.85–8.37; P = 0.0002), invasive procedures (OR 3.06, 95 % CI 1.61–5.8; P = 0.0004), and intensive care unit admission (OR 2.49, 95 % CI 1.18–5.37; P = 0.015).
Bacteriuria caused by CRKp as compared that caused by CSKp was not found to be a risk factor for death.
- Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40. CrossRef
- Gona F, Mezzatesta ML, Corona D, Zerbo D, Scriffignano V, Stefani S, Veroux P, Veroux M. Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit. Infection. 2011;39:83–5. CrossRef
- Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36. CrossRef
- Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis. 2003;22:158–64.
- MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet. 2007;350:783. CrossRef
- Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50:3098–101. CrossRef
- Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12:1209–13. CrossRef
- Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y. Containment of a country-wide outbreak of carbapenem resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52:848–55. CrossRef
- Wiener-Well Y, Rudensky B, Yinnon AM, et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalized patients during a national outbreak. J Hosp Infect. 2010;74:344–9. CrossRef
- Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124–30. CrossRef
- Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2007;52:1028–33. CrossRef
- Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60. CrossRef
- Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist. 2005;11:165–9. CrossRef
- Cope M, Cevallos ME, Cadle RM, Darouiche RO, Musher DM, Trautner BW. Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care hospital. Clin Infect Dis. 2009;48:1182–8. CrossRef
- Bradford PA, Bratu S, Urban C. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004;39:55–60. CrossRef
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th International supplement. CLSI document M100-S10. Wayne: Clinical Laboratory Standards Institute; 2009.
- Henschke R, Yinnon AM, Rudensky B, Attias D, Raveh D. Assessment of the clinical significance of production of extended-spectrum-β-lactamase (ESBL) by Enterobacteriaceae. Infection. 2006;34:66–74. CrossRef
- Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem, and piperacillin-tazobactam, with and without clavulanic acid. Chemotherapy. 2007;53:185–9. CrossRef
- Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B. Klebsiella bacteraemia: community versus nosocomial infection. Q J Med. 1996;89:933–41. CrossRef
- Bahagon Y, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Prevalence and predictive features of bacteremic urinary tract infection in emergency department patients. Eur J Clin Microbiol Infect Dis. 2007;26:349–52. CrossRef
- Marchi M, Grilli E, Mongardi M, Bedosti C, Nobilio L, Moro ML. Prevalence of infections in long-term care facilities: how to read it? Infection. 2012;40:493–500. CrossRef
- Burke JP. Nosocomial urinary tract infections. In: Mayhall CG, editor. Hospital epidemiology infection control. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 267–86.
- Salgavo CD. Prevention of catheter associated urinary tract infection. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 297–311.
- Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem resistant pneumonia bacteremia. Infect Control Hosp Epidemiol. 2009;30:972–6. CrossRef
- Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106. CrossRef
- Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25:860–7. CrossRef
- Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 2010;31:620–6. CrossRef
- Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gram-negatives; therapeutic approach and infection control. Clin Microbiol Infect. 2010;16:102–11. CrossRef
- Miriagou V, Cornaglia G, Edelstein M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112–22. CrossRef
- Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case–control study
Volume 41, Issue 2 , pp 503-509
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Carbapenem resistance
- Klebsiella pneumoniae
- Multi-drug resistance
- Urinary tract infection
- Nosocomial infection
- Industry Sectors
- Author Affiliations
- 1. Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel
- 2. Clinical Microbiology Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel
- 3. Hebrew University–Hadassah Medical School, Jerusalem, Israel
- 4. Division of Internal Medicine, Shaare Zedek Medical Center, P.O. Box 3235, 91031, Jerusalem, Israel